Antibody Response and Adverse Events of AZD1222 COVID-19 Vaccination in Patients Undergoing Dialysis: A Prospective Cohort Study

doi:10.3390/vaccines10091460

. 2022 Sep 3;10(9):1460.

doi: 10.3390/vaccines10091460.

Antibody Response and Adverse Events of AZD1222 COVID-19 Vaccination in Patients Undergoing Dialysis: A Prospective Cohort Study

Hsi-Hao Wang^{1

2

3}, Jia-Ling Wu⁴, Min-Yu Chang^{1

2}, Hsin-Mian Wu⁵, Li-Chun Ho^{1

2}, Po-Jui Chi^{1

2}, Ching-Fang Wu^{1

2

6}, Wan-Chia Lee⁷, Hung-Hsiang Liou⁸, Shih-Yuan Hung^{1

2}, Yi-Che Lee^{1

2

9}

Affiliations

¹ Division of Nephrology, Department of Internal Medicine, E-DA Hospital, Kaohsiung 82445, Taiwan.
² School of Medicine, College of Medicine, I-Shou University, Kaohsiung 84001, Taiwan.
³ Department of Medical Quality, E-DA Hospital, Kaohsiung 82445, Taiwan.
⁴ Department of Public Health, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.
⁵ Department of Laboratory Medicine, E-DA Hospital, Kaohsiung 82445, Taiwan.
⁶ Division of Nephrology, Department of Internal Medicine, E-DA Cancer Hospital, Kaohsiung 82445, Taiwan.
⁷ Department of Rehabilitation, Kaohsiung Municipal United Hospital, Kaohsiung 80457, Taiwan.
⁸ Division of Nephrology, Department of Internal Medicine, Hsin-Jen Hospital, New Taipei City 23561, Taiwan.
⁹ Division of Nephrology, Department of Internal Medicine, E-DA Dachang Hospital, Kaohsiung 82445, Taiwan.

PMID: 36146538
PMCID: PMC9501178
DOI: 10.3390/vaccines10091460

Antibody Response and Adverse Events of AZD1222 COVID-19 Vaccination in Patients Undergoing Dialysis: A Prospective Cohort Study

Hsi-Hao Wang et al. Vaccines (Basel). 2022.

. 2022 Sep 3;10(9):1460.

doi: 10.3390/vaccines10091460.

Authors

Affiliations

¹ Division of Nephrology, Department of Internal Medicine, E-DA Hospital, Kaohsiung 82445, Taiwan.
² School of Medicine, College of Medicine, I-Shou University, Kaohsiung 84001, Taiwan.
³ Department of Medical Quality, E-DA Hospital, Kaohsiung 82445, Taiwan.
⁴ Department of Public Health, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.
⁵ Department of Laboratory Medicine, E-DA Hospital, Kaohsiung 82445, Taiwan.
⁶ Division of Nephrology, Department of Internal Medicine, E-DA Cancer Hospital, Kaohsiung 82445, Taiwan.
⁷ Department of Rehabilitation, Kaohsiung Municipal United Hospital, Kaohsiung 80457, Taiwan.
⁸ Division of Nephrology, Department of Internal Medicine, Hsin-Jen Hospital, New Taipei City 23561, Taiwan.
⁹ Division of Nephrology, Department of Internal Medicine, E-DA Dachang Hospital, Kaohsiung 82445, Taiwan.

PMID: 36146538
PMCID: PMC9501178
DOI: 10.3390/vaccines10091460

Abstract

This study observed the antibody response and adverse events of AZD1222 (Oxford/AstraZeneca) vaccination in dialysis patients. A prospective cohort study was conducted in E-Da Healthcare Group hospitals between 1 July and 30 November 2021. Patients receiving hemodialysis (HD, n = 204) or peritoneal dialysis (PD, n = 116) were enrolled alongside healthy subjects (control, n = 34). Anti-SARS-CoV-2 S1 RBD IgG antibodies were measured before the first vaccination (T0), four to six weeks afterwards (T1), one week before the second dose (T2), and four to six weeks afterwards (T3). Adverse events were recorded one week after each dose. The positive IgG rates in the HD (T1: 72%; T2: 62%) and PD (T1: 69%; T2: 70%) groups were lower than the control group (T1: 97%; T2: 91%), with lower median antibody titers. At T3, the positive antibody response rates (HD: 94%; PD: 93%; control: 100%) and titers were similar. Titers were higher after the second dose in all groups. Adverse events were more severe after the first dose and less common with HD than PD or controls. Dialysis patients exhibited lower antibody responses than controls after the first dose of the AZD1222 vaccine but achieved similar responses after consecutive vaccination. Age, health status, two vaccine doses, and alcohol consumption may influence antibody levels.

Keywords: AZD1222; COVID-19; adverse events; antibody response; cohort study; dialysis; hemodialysis; peritoneal dialysis; vaccination.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

**Figure 3**
SARS-CoV-2 RBD IgG antibody titer values by group and time (T1 vs. T2 vs. T3). ^∔ HD vs. Control (p-value < 0.05), ^⧺ PD vs. Control (p-value < 0.05), * p-value < 0.05.

**Figure 4**
Local (on the left side of dotted line) and systemic (on the right side of dotted line) adverse events (AE) after the first and second vaccination with AZD1222. ^∔ HD vs. Control, p-value < 0.05, ^⧺ PD vs. Control, p-value < 0.05, ^⧻ HD vs. PD, p-value < 0.05.

See this image and copyright information in PMC

Cited by

18-month longitudinal SARS COV-2 neutralizing antibody dynamics in haemodialysis patients receiving heterologous 3-dose vaccination (AZD-1222- AZD-1222- BNT162b2) in a lower middle income setting.
Karunathilake RP, Kumara RA, Karunathilaka A, Wazil AWM, Nanayakkara N, Bandara CK, Abeysekera RA, Noordeen F, Gawarammana IB, Ratnatunga CN. Karunathilake RP, et al. BMC Nephrol. 2024 May 22;25(1):176. doi: 10.1186/s12882-024-03599-7. BMC Nephrol. 2024. PMID: 38778281 Free PMC article.
Outcomes of vaccinations against respiratory diseases in patients with end-stage renal disease undergoing hemodialysis: A systematic review and meta-analysis.
Puspitasari M, Sattwika PD, Rahari DS, Wijaya W, Hidayat ARP, Kertia N, Purwanto B, Thobari JA. Puspitasari M, et al. PLoS One. 2023 Feb 9;18(2):e0281160. doi: 10.1371/journal.pone.0281160. eCollection 2023. PLoS One. 2023. PMID: 36757979 Free PMC article.

References

1. Hu B., Guo H., Zhou P., Shi Z.L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 2021;19:141–154. doi: 10.1038/s41579-020-00459-7. - DOI - PMC - PubMed
1. Anand S., Montez-Rath M.E., Han J., Garcia P., Cadden L., Hunsader P., Kerschmann R., Beyer P., Dittrich M., Block G.A., et al. Antibody Response to COVID-19 vaccination in Patients Receiving Dialysis. medRxiv. 2021;181:281–292. doi: 10.1681/ASN.2021050611. - DOI - PMC - PubMed
1. Centers for Disease Control and Prevention (CDC) Vaccinating Dialysis Patients and Healthcare Personnel. [(accessed on 7 June 2022)]; Available online: https://www.cdc.gov/vaccines/covid-19/planning/vaccinate-dialysis-patien....
1. Hsu C.M., Weiner D.E., Aweh G., Miskulin D.C., Manley H.J., Stewart C., Ladik V., Hosford J., Lacson E.C., Johnson D.S., et al. COVID-19 Among US Dialysis Patients: Risk Factors and Outcomes from a National Dialysis Provider. Am. J. Kidney Dis. 2021;77:748–756.E1. doi: 10.1053/j.ajkd.2021.01.003. - DOI - PMC - PubMed
1. Mahallawi W.H., Ibrahim N.A., Mumena W.A. Effectiveness of COVID-19 Vaccines in Patients Under Maintenance Hemodialysis. Risk Manag. Healthc. Policy. 2021;14:5081–5088. doi: 10.2147/RMHP.S345686. - DOI - PMC - PubMed

Grants and funding

EDAHP111010/E-Da hospital

LinkOut - more resources

Full Text Sources
Miscellaneous
- NCI CPTAC Assay Portal

[1] Hu B., Guo H., Zhou P., Shi Z.L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 2021;19:141–154. doi: 10.1038/s41579-020-00459-7. - DOI - PMC - PubMed

[2] Hu B., Guo H., Zhou P., Shi Z.L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 2021;19:141–154. doi: 10.1038/s41579-020-00459-7. - DOI - PMC - PubMed

[3] Anand S., Montez-Rath M.E., Han J., Garcia P., Cadden L., Hunsader P., Kerschmann R., Beyer P., Dittrich M., Block G.A., et al. Antibody Response to COVID-19 vaccination in Patients Receiving Dialysis. medRxiv. 2021;181:281–292. doi: 10.1681/ASN.2021050611. - DOI - PMC - PubMed

[4] Anand S., Montez-Rath M.E., Han J., Garcia P., Cadden L., Hunsader P., Kerschmann R., Beyer P., Dittrich M., Block G.A., et al. Antibody Response to COVID-19 vaccination in Patients Receiving Dialysis. medRxiv. 2021;181:281–292. doi: 10.1681/ASN.2021050611. - DOI - PMC - PubMed

[5] Centers for Disease Control and Prevention (CDC) Vaccinating Dialysis Patients and Healthcare Personnel. [(accessed on 7 June 2022)]; Available online: https://www.cdc.gov/vaccines/covid-19/planning/vaccinate-dialysis-patien....

[6] Centers for Disease Control and Prevention (CDC) Vaccinating Dialysis Patients and Healthcare Personnel. [(accessed on 7 June 2022)]; Available online: https://www.cdc.gov/vaccines/covid-19/planning/vaccinate-dialysis-patien....

[7] Hsu C.M., Weiner D.E., Aweh G., Miskulin D.C., Manley H.J., Stewart C., Ladik V., Hosford J., Lacson E.C., Johnson D.S., et al. COVID-19 Among US Dialysis Patients: Risk Factors and Outcomes from a National Dialysis Provider. Am. J. Kidney Dis. 2021;77:748–756.E1. doi: 10.1053/j.ajkd.2021.01.003. - DOI - PMC - PubMed

[8] Hsu C.M., Weiner D.E., Aweh G., Miskulin D.C., Manley H.J., Stewart C., Ladik V., Hosford J., Lacson E.C., Johnson D.S., et al. COVID-19 Among US Dialysis Patients: Risk Factors and Outcomes from a National Dialysis Provider. Am. J. Kidney Dis. 2021;77:748–756.E1. doi: 10.1053/j.ajkd.2021.01.003. - DOI - PMC - PubMed

[9] Mahallawi W.H., Ibrahim N.A., Mumena W.A. Effectiveness of COVID-19 Vaccines in Patients Under Maintenance Hemodialysis. Risk Manag. Healthc. Policy. 2021;14:5081–5088. doi: 10.2147/RMHP.S345686. - DOI - PMC - PubMed

[10] Mahallawi W.H., Ibrahim N.A., Mumena W.A. Effectiveness of COVID-19 Vaccines in Patients Under Maintenance Hemodialysis. Risk Manag. Healthc. Policy. 2021;14:5081–5088. doi: 10.2147/RMHP.S345686. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Antibody Response and Adverse Events of AZD1222 COVID-19 Vaccination in Patients Undergoing Dialysis: A Prospective Cohort Study

Affiliations

Antibody Response and Adverse Events of AZD1222 COVID-19 Vaccination in Patients Undergoing Dialysis: A Prospective Cohort Study

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Grants and funding

LinkOut - more resources

Full Text Sources

Miscellaneous